Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2003

View Archived Issues

Nycomed obtains marketing license for Almogran in Nordic region

FluINsure delivers strong immunogenicity data in phase II trials

Amylin submits NDA amendment for Symlin

Data reported for pramipexole in Parkinson's disease and restless legs syndrome

Novel series of acylides with potent in vivo activity against Gram-positive pathogens

Effective stimulation of erythropoiesis reported for CERA in preclinical and clinical studies

LY-307161 SR confirmed to be an effective glucose-lowering drug in type 2 diabetes

Improved glycemic control with inhaled insulin compared to rosiglitazone in type 2 diabetics

Ruboxistaurin in diabetic neuropathy and retinopathy

Two studies confirm the potential benefits of NN-414 in type 2 diabetes

NN-2211 improves glycemia and sensitivity to glucose in patients with type 2 diabetes

Genentech and Biogen collaborate on BR3 protein therapeutic

Arixtra approved for extended use

Hollis-Eden and CFFT study HE-2000 in cystic fibrosis

Gaboxadol enters phase III testing for primary insomnia

MCH1 antagonist reduces body weight gain by decreasing food intake

Potential of EB-1089 in the treatment of B-CLL

Roche claims two novel series of A2A receptor ligands

Ezetimibe approved in Canada

New BCAT inhibitors and their use claimed by the former Warner-Lambert

Novel antiobesity MCH antagonists in early development at Schering-Plough

Nippon Chemiphar patent covers new xanthine oxidase inhibitors for use in gout and hyperuricemia

Dual adenosine A1/A2A antagonists in Fujisawa development pipeline

Pfizer researchers describe new neuronal nAChR ligands for nicotine addiction

New antiplatelet agent of fungal origin identified by Aventis

Shiseido synthesizes new MMP inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...